← Evidence map

ArticleCancer medicine2022

A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations.

Hong-Shuai Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

5 papers cite it

2022

2023

this papercites it

A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations. | OpenQuestion